CureGene Achieves First Participant Dosed in U.S. Pivotal Trial for Evategrel (CG-0255), a Best-in-Class Antiplatelet Drug, Accelerating Global Commercialization

SHANGHAI, June 20, 2026 /PRNewswire/ — CureGene Pharmaceutical today announced that the first participant has been successfully dosed in the U.S. pivotal clinical trial of Evategrel (CG-0255), its proprietary new-generation best-in-class antiplatelet agent. This milestone marks a…

Healthcare Insights Desk

Welcome to the Healthcare Insights Desk at TheUnplanned.in, where we delve deep into the world of health and wellness. Our dedicated team of writers brings you authoritative articles, expert opinions, and insightful analyses on all facets of healthcare.


Discover more from The Unplanned

Subscribe to get the latest posts sent to your email.

Scroll to Top

Discover more from The Unplanned

Subscribe now to keep reading and get access to the full archive.

Continue reading

Verified by MonsterInsights